AR and prostate carcinoma: Similar to our findings, Tolmeijer and colleagues [26] found a strong link between ctDNA at baseline and OS in a group of advanced castrate-resistant prostate cancer patients, but the changes from high to low ctDNA levels at 4 weeks of androgen receptor inhibition was not correlated with OS.